Top-Rated StocksTop-RatedNASDAQ:BEAM Beam Therapeutics (BEAM) Stock Price, News & Analysis $16.64 +0.63 (+3.94%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$16.71 +0.07 (+0.42%) As of 08/22/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Beam Therapeutics Stock (NASDAQ:BEAM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Beam Therapeutics alerts:Sign Up Key Stats Today's Range$16.04▼$17.1250-Day Range$16.01▼$22.1652-Week Range$13.52▼$35.25Volume2.39 million shsAverage Volume2.49 million shsMarket Capitalization$1.68 billionP/E RatioN/ADividend YieldN/APrice Target$48.45Consensus RatingBuy Company Overview Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts. Read More Beam Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreBEAM MarketRank™: Beam Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 684th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBeam Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.07, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageBeam Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Beam Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Beam Therapeutics are expected to grow in the coming year, from ($4.57) to ($4.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Beam Therapeutics is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Beam Therapeutics is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBeam Therapeutics has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Beam Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.22% of the float of Beam Therapeutics has been sold short.Short Interest Ratio / Days to CoverBeam Therapeutics has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.Change versus previous monthShort interest in Beam Therapeutics has recently increased by 4.06%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBeam Therapeutics does not currently pay a dividend.Dividend GrowthBeam Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted25.22% of the float of Beam Therapeutics has been sold short.Short Interest Ratio / Days to CoverBeam Therapeutics has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.Change versus previous monthShort interest in Beam Therapeutics has recently increased by 4.06%, indicating that investor sentiment is decreasing. News and Social Media2.7 / 5News Sentiment0.86 News SentimentBeam Therapeutics has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Beam Therapeutics this week, compared to 7 articles on an average week.Search InterestOnly 22 people have searched for BEAM on MarketBeat in the last 30 days. This is a decrease of -21% compared to the previous 30 days.MarketBeat Follows14 people have added Beam Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Beam Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,015,628.00 in company stock.Percentage Held by InsidersOnly 3.50% of the stock of Beam Therapeutics is held by insiders.Percentage Held by Institutions99.68% of the stock of Beam Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Beam Therapeutics' insider trading history. Receive BEAM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BEAM Stock News HeadlinesFmr Llc Sells 48,374 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) StockAugust 2, 2025 | insidertrades.comCathie Wood’s ARK Investment buys 509.6K shares of Beam Therapeutics todayAugust 20 at 8:49 PM | msn.comBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. | Crypto 101 Media (Ad)JonesTrading Reduces the PT on Beam Therapeutics (BEAM), Keeps a Buy RatingAugust 20 at 2:38 AM | msn.comCathie Wood’s ARK Investment buys 395K shares of Beam Therapeutics todayAugust 19, 2025 | msn.comBeam Therapeutics: A Slow-Developing StoryAugust 17, 2025 | seekingalpha.comBank of America Securities Keeps Their Buy Rating on Beam Therapeutics (BEAM)August 15, 2025 | theglobeandmail.comBeam Therapeutics (BEAM) Receives a Buy from Leerink PartnersAugust 14, 2025 | theglobeandmail.comSee More Headlines BEAM Stock Analysis - Frequently Asked Questions How have BEAM shares performed this year? Beam Therapeutics' stock was trading at $24.80 on January 1st, 2025. Since then, BEAM shares have decreased by 32.9% and is now trading at $16.64. How were Beam Therapeutics' earnings last quarter? Beam Therapeutics Inc. (NASDAQ:BEAM) released its earnings results on Tuesday, August, 5th. The company reported ($1.00) earnings per share for the quarter, topping analysts' consensus estimates of ($1.04) by $0.04. The business's revenue was down 28.0% on a year-over-year basis. Does Beam Therapeutics have any subsidiaries? Beam Therapeutics subsidiaries include these companies: Blink Therapeutics Inc.. When did Beam Therapeutics IPO? Beam Therapeutics (BEAM) raised $101 million in an initial public offering (IPO) on Thursday, February 6th 2020. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Beam Therapeutics' major shareholders? Top institutional shareholders of Beam Therapeutics include ARK Investment Management LLC (8.80%), Sumitomo Mitsui Trust Group Inc. (4.70%), Nikko Asset Management Americas Inc. (4.67%) and Bellevue Group AG (2.86%). Insiders that own company stock include Fmr Llc, John M Evans, Giuseppe Ciaramella, Christine Bellon, Terry-Ann Burrell, Amy Simon and Bethany J Cavanagh. View institutional ownership trends. How do I buy shares of Beam Therapeutics? Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Beam Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Beam Therapeutics investors own include Chevron (CVX), Bristol Myers Squibb (BMY), Comcast (CMCSA), Charles Schwab (SCHW), Edwards Lifesciences (EW), McKesson (MCK) and Yum! Brands (YUM). Company Calendar Last Earnings8/05/2025Today8/22/2025Next Earnings (Estimated)11/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BEAM CIK1745999 Webwww.beamtx.com Phone857-327-8775FaxN/AEmployees510Year Founded2017Price Target and Rating Average Price Target for Beam Therapeutics$48.45 High Price Target$80.00 Low Price Target$21.00 Potential Upside/Downside+191.2%Consensus RatingBuy Rating Score (0-4)3.07 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($4.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$376.74 million Net Margins-661.31% Pretax Margin-661.31% Return on Equity-43.15% Return on Assets-31.06% Debt Debt-to-Equity RatioN/A Current Ratio6.75 Quick Ratio6.75 Sales & Book Value Annual Sales$63.52 million Price / Sales26.50 Cash FlowN/A Price / Cash FlowN/A Book Value$10.35 per share Price / Book1.61Miscellaneous Outstanding Shares101,160,000Free Float97,621,000Market Cap$1.68 billion OptionableOptionable Beta2.22 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:BEAM) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.